mmitted to working together with biological medicines and biosimilar manufacturers, health care professionals, patient groups and other key stakeholders to ensure patient safety is at the forefront of the biological policy discussion???, commentedEuropaBio Biosimilar topic group leader Stefan Bergunde.???Biological medicines cannot be copied in the same way as small molecule drugs can be, so diffe